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Beckwith-Wiedemann syndrome (BWS) is a congenital cancer-predisposition syndrome associated with embryonal
cancers, macroglossia, macrosomia, ear pits or ear creases, and midline abdominal-wall defects. The most common
constitutional abnormalities in BWS are epigenetic, involving abnormal methylation of either H19 or LIT1, which
encode untranslated RNAs on 11p15. We hypothesized that different epigenetic alterations would be associated
with specific phenotypes in BWS. To test this hypothesis, we performed a case-cohort study, using the BWS Registry.
The cohort consisted of 92 patients with BWS and molecular analysis of both H19 and LIT1, and these patients
showed the same frequency of clinical phenotypes as those patients in the Registry from whom biological samples
were not available. The frequency of altered DNA methylation ofH19 in patients with cancer was significantly higher,
56% (9/16), than the frequency in patients without cancer, 17% (13/76; ), and cancer was not associatedPp .002
with LIT1 alterations. Furthermore, the frequency of altered DNA methylation of LIT1 in patients with midline
abdominal-wall defects and macrosomia was significantly higher, 65% (41/63) and 60% (46/77), respectively, than
in patients without such defects, 34% (10/29) and 18% (2/11), respectively ( and , respectively).Pp .012 Pp .02
Additionally, paternal uniparental disomy (UPD) of 11p15 was associated with hemihypertrophy ( ), cancerPp .003
( ), and hypoglycemia ( ). These results define an epigenotype-phenotype relationship in BWS, in whichPp .03 Pp .05
aberrant methylation of H19 and LIT1 and UPD are strongly associated with cancer risk and specific birth defects.
Introduction
Beckwith-Wiedemann syndrome (BWS [MIM 130650])
is a model for the understanding of the role of epigenetics
in cancer, since it involves frequent alterations in the
imprinting and methylation of several genes on chro-
mosomal band 11p15, including insulin-like growth fac-
tor-II (IGF2 [MIM 147470]), H19 (MIM 103280),
p57KIP2 (or CDKN1C [MIM 600856]), KvLQT1 (MIM
192500), and LIT1 (MIM 604115). Genomic imprint-
ing is a gene modification that typically involves DNA
methylation but may include other factors as well and
that leads to the relative silencing of a specific parental
allele in somatic cells of the offspring. The phenotypic
features of BWS are macrosomia, neonatal hypoglyce-
mia, midline abdominal defects (e.g., omphalocele, dias-
tasis recti, and umbilical hernia), macroglossia, and ear
pits or ear creases, as well as an increased incidence of
Received October 29, 2001; accepted for publication November 29,
2001; electronically published January 28, 2002.
Address for correspondence and reprints: Dr. Andrew P. Feinberg,
Johns Hopkins University School ofMedicine, 1064Ross, 720Rutland
Avenue, Baltimore, MD 21204. E-mail: afeinberg@jhu.edu
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7003-0006$15.00
embryonal cancers in infants and young children. The
most frequent cancer is Wilms tumor, occurring in 11%
of children with BWS before 4 years of age, followed in
frequency by other embryonal tumors, including hepa-
toblastoma and neuroblastoma (DeBaun and Tucker
1998). Other cancers occurring with lower frequency in
this population include rhabdomyosarcoma and adreno-
cortical carcinoma.
The epigenetics of BWS is complex. Six genetic or
epigenetic alterations in patients with BWS have been
described:
1. Loss of imprinting (LOI) of IGF2 in embryonal
tumors and in the normal cells of patients with BWS,
which, in BWS, involves activation of the normally silent
maternally inherited allele of IGF2 (Ogawa et al. 1993;
Rainier et al. 1993; Weksberg et al. 1993). Most inves-
tigators report a frequency of ∼10%–15% (Elias et al.
1998; Lee et al. 1999), but one study suggests a higher
frequency (Joyce et al. 1997).
2. Abnormal methylation of the normally unmethy-
lated allele of a differentially methylated region (DMR)
upstream from H19 (Steenman et al. 1994; Reik et al.
1995). The H19 DMR serves as a site for the binding
of the insulator protein CTCF, and it inhibits access of
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the maternal allele of IGF2 to a shared enhancer down-
stream from H19 (reviewed by Feinberg [2001]). In the
case of Wilms tumor, LOI of IGF2 is coupled to ab-
normal H19 methylation (Moulton et al. 1994; Steen-
man et al. 1994). In the case of BWS, there may also be
an independent mechanism for regulating IGF2 in these
patients (Joyce et al. 1997). The frequency of this alter-
ation is 15% (reviewed by Elias et al. [1998]).
3. Germline chromosomal rearrangements. We showed
that balanced rearrangements interrupt the KvLQT1
gene (Lee et al. 1997b), and there are also rare unbal-
anced duplications (reviewed by Elias et al. [1998]).
4. Mutations of the p57KIP2 gene, which are rare (Lee
et al. 1997a; O’Keefe et al. 1997).
5. LOI of LIT1, shown directly by us (Lee et al. 1999)
and indirectly by others (Smilinich et al. 1999). LIT1 is
an antisense transcript that is normally expressed from
the paternal allele and lies within the KvLQT1 gene (Lee
et al. 1999; Smilinich et al. 1999), and LOI of LIT1 is
completely linked to abnormal methylation of a DMR
upstream from the gene (Lee et al. 1999). This is the
most frequent abnormality in BWS, accounting for
40%–50% of patients.
6. Paternal uniparental disomy (UPD) of 11p15, oc-
curring in ∼10% of patients (reviewed by Elias et al.
[1998]).
We hypothesized that there may be a relationship be-
tween cancer risk and LOI of IGF2 and/or aberrant
methylation of the H19 DMR, because we and others
have described both defects in the general population,
in the same type of embryonal cancers found in children
with BWS (Ogawa et al 1993; Rainier et al. 1993; Steen-
man et al. 1994). In contrast, we and others have found
no alterations in LIT1, p57KIP2, or KvLQT1 in embry-
onal tumors (Reid et al. 1996; Mitsuya et al. 1999; M.
P. Lee and A. P. Feinberg, unpublished data), suggesting
specificity of the H19/IGF2 subdomain in embryonal
tumors. In preliminary data, we described the associa-
tion between abnormal H19 methylation and increased
cancer risk in BWS (Niemitz et al. 2001). In addition,
Bliek et al. (2001) documented an association between
aberrant H19 methylation and cancer; however, in that
study, it was unclear whether cancer was specific for
abnormal H19 methylation or UPD, as there were only
two cancer patients with abnormal H19 methylation in
the absence of UPD. Additionally, Engel et al. (2000)
described a 69% (20 of 29) frequency of midline ab-
dominal-wall defects in patients with abnormal meth-
ylation ofLIT1, but they did not compare this frequency
to all patients with BWS without abnormal LIT1meth-
ylation, so it cannot be determined whether this fre-
quency is elevated. Because of small numbers of patients
in both studies, discrimination of phenotypic associa-
tion for UPD versus the individual affected genes could
not be done. Both studies most likely had strong as-
certainment bias, since children with either cancer or
midline abdominal-wall defects who required surgery
were probably referred to tertiary care centers. The cur-
rent study addressed a large non–tertiary-care-center–
based registry of children with BWS, and it represents
the first report of BWS to examine multiple phenotypes
associated with a given epigenotype, allowing the def-
inition of epigenotype-phenotype relationships.
Patients and Methods
Patients
We established the BWS Registry in 1994 at the Ge-
netic Epidemiology Branch of the National Cancer In-
stitute to understand the natural history of this syndrome
and to determine whether genotype-phenotype relation-
ships exist. For those families who agreed to participate,
a comprehensive questionnaire was completed, and in-
formed consent and medical-information–release docu-
ments were obtained, as approved by the respective in-
stitutional review boards. For the purposes of this study,
we defined a patient as having BWS if a clinical diagnosis
of BWS had been made by a physician and the patient
had at least two of the five most common features as-
sociated with BWS (Pettenati et al. 1986): (1) macroglos-
sia, (2) birth weight and length 190th percentile, (3)
hypoglycemia in the first month of life, (4) ear creases
or ear pits, and (5) midline abdominal-wall defects (om-
phalocele, diastasis recti, and umbilical hernia). All pos-
itive phenotypic features were diagnosed by a physician
and were documented in the questionnaire. The local
physician defined idiopathic hemihypertrophy. In four
patients, birth weight and length were unknown, and,
thus, macrosomia could not be scored in those four pa-
tients. If a cancer was reported, the diagnosis was con-
firmed by review of the final pathology report and med-
ical records. Among the patients studied, there were 16
embryonal tumors, including 13 Wilms tumors, 2 he-
patoblastomas, and 1 rhabdomyosarcoma. The geno-
types of all patients were not known prior to entering
the registry. All molecular analyses were performed
blinded for knowledge of the phenotype.
Isolation of DNA
Genomic DNA was prepared from peripheral-blood
lymphocytes (2/3 of patients) or cultured skin fibroblasts
(1/3 of patients) by standard proteinase K digestion and
phenol extraction (Cui et al. 1998). This material is suit-
able for methylation assays involving DNA.
Analysis of H19 Methylation
A 1.8-kb PstI fragment of the H19 gene (nucleotides
1–1803 of the human H19 probe [GenBank accession
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number M32053]) was analyzed for DNA methylation
by digestion with PstI and SmaI. Ten micrograms of
DNA were digested at 25C overnight with 40 U of
SmaI, followed by an additional incubation at 37C for
4 h with 40 U of PstI. The digested DNA was electro-
phoresed on a 1% agarose gel, was transferred to Hy-
bond-N (Amersham), and was hybridized with the 1-
kb PstI  SmaI fragment isolated from an H19 genomic
clone and oligolabeled with a-[32P]-dATP. Signals were
quantified using a PhosphorImager (Molecular Dynam-
ics). Abnormal methylation in lymphocytes was defined
as a methylation index of 10.63 (mean  2 SD of 15
normal individuals). DNA samples were available from
blood or fibroblasts but not both from any given patient.
Fibroblasts from normal individuals ( ) showed anp 5
methylation index of ∼0.33. All of the BWS fibroblast
samples showed a methylation index of ∼0.33 (scored
as normal) or ∼0.66 (scored as abnormal). There was
no difference in the frequency of increased methylation
when comparing BWS samples from lymphocytes or
BWS samples from fibroblasts. Furthermore, the asso-
ciation between abnormal H19 methylation and cancer
was unchanged when the fibroblast samples were
excluded.
Analysis of LIT1 Methylation
Ten micrograms of DNA were digested with BamHI
and NotI at 37C overnight. The digested DNA was
electrophoresed on a 1% agarose gel, was transferred
to Hybond-N (Amersham), and was hybridized with
an expressed-sequence–tag probe (GenBank accession
number AA155639) oligolabeled with a-[32P]-dATP. Sig-
nals were quantified using a PhosphorImager (Molecular
Dynamics). Abnormal methylation was defined as a
methylation index of !0.39 (mean  2 SD of 15 normal
individuals). The methylation index of LIT1 was un-
changed in cultured skin fibroblasts.
Analysis of UPD
Patients who were determined to have epigenetic al-
terations at both BWS loci tested (i.e., to have hyper-
methylation ofH19 and hypomethylation of LIT1) were
evaluated for paternal UPD of 11p15.5. Patient and ma-
ternal DNA samples were genotyped with a panel of
three microsatellite markers: D11S1318, D11S988, and
D11S922. PCR primer sequences were obtained from
the Genome Database. PCR was performed as recom-
mended by the Genome Database by use of FAM-labeled
primer pairs. PCR products were then analyzed by elec-
trophoresis on a model 377 automated fluorescent DNA
sequencer (Applied Biosystems). The raw data were an-
alyzed using Genescan software (Applied Biosystems).
The peak data generated by Genescan were then ana-
lyzed using the Genotyper program (Applied Biosys-
tems). Patients in whose DNA the Genescan software
indicated that the maternal allele(s) was absent were con-
sidered to have UPD; however, examination of the chro-
matograms for those patients revealed a small peak
(!20% of the scored allele), corresponding to one of the
maternal alleles and thereby indicating mosaicism for
UPD for each patient.
Statistical Analysis
A statistic and Fisher’s exact test were used to de-2x
termine whether specific epigenotypes (aberrant meth-
ylation of either H19 or LIT1 or UPD of 11p15) were
associated with the presence of specific phenotypes in
children with BWS. When the expected value in a given
cell was !5, Fisher’s exact test was used (Glantz 1992).
A P value !.05 was considered statistically significant.
In addition, the odds ratio for cancer was calculated and
was considered to be significantly increased if it was 11.0
and if the 95% confidence intervals (95%CIs) did not
include 1.0.
Results
Comparison of Patients with BWS, with and without
Molecular Analysis
A total of 279 children have met the criteria to be
included in the BWS Registry, of whom material could
be obtained from 92 for analysis of both LIT1 andH19
methylation and UPD. The average age of patients who
provided biological specimens was 5.6 years, and the
age range was 1 mo–30 years. Of the patients, 52%
were male, and, of the parents, 87% identified them-
selves as white, 2% identified themselves as African
American, 7% identified themselves as Hispanic, 2%
identified themselves as Asian, and 2% identified them-
selves as Native American. No significant phenotypic
differences were identified between patients who were
molecularly analyzed and those who were not, including
frequency of cancer, macroglossia, hypoglycemia, ab-
dominal-wall defects, macrosomia, ear pits or creases,
and hemihypertrophy (table 1). These findings indicate
that the cohort of children with biological specimens in
the BWS Registry were representative of the entire BWS
Registry.
Frequency of Genotypes
The most frequent molecular alteration observed in
children with BWS was altered LIT1 methylation with
normal H19 methylation (42% [39/92 patients]). The
frequency of alteredH19methylation with normalLIT1
methylation was 11% (10/92 patients). Twelve patients
(13%) exhibited altered methylation of both H19 and
LIT1. We expected that these patients would show pa-
ternal UPD, since, in UPD, both maternal copies are
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Table 1
Comparison of Patients with BWS, with and without Molecular
Analysis
PHENOTYPE
% WITH PHENOTYPE
Pa
With
Molecular
Analysis
(n p 92)
Without
Molecular
Analysis
(n p 187)
Macrosomia 88 53 .25
Ear grooves/pits 63 71 .17
Abdominal-wall defects 68 76 .15
Hypoglycemia 53 52 .83
Macroglossia 97 92 .16
Hemihypertrophy 36 32 .47
Embryonal cancer 16 19 .08
a Calculated by analysis.2x
replaced with a paternal copy that alters the methylation
pattern of both genes. Unexpectedly, of these 12 patients,
9 showed UPD, and the remaining 3 exhibited altered
methylation of both H19 and LIT1 in the absence of
UPD. These patients therefore had an imprinting dis-
turbance extending throughout the 11p15 imprinted-
gene domain, which has not been described elsewhere.
Association of Cancer with Altered H19 Methylation
Abnormal H19 methylation was associated with an
elevated risk for embryonal cancer (table 2). The fre-
quency of altered H19 methylation in patients with em-
bryonal cancer was significantly greater than that in pa-
tients without cancer—56% (9/16) versus 17% (13/76),
respectively ( ). The odds ratio for cancer inPp .002
children with altered H19 methylation was 6.2 (95%CI
1.7–19.8). In contrast, alteredLIT1methylationwas not
associated with an elevated risk for embryonal cancer
(table 2). We also determined whether the increased fre-
quency of altered H19 methylation in patients with can-
cer was specific for H19 or was simply due to UPD or
an imprinting disturbance extending throughout the
11p15 imprinted-gene domain. To address this possi-
bility, we excluded patients with UPD ( ) or withnp 9
aberrant methylation of both H19 and LIT1 ( )np 3
from the analysis; with the exclusion of these 12 patients,
the frequency of altered H19 methylation among pa-
tients with embryonal cancer was still significantly
higher than that in patients without cancer—36% (4/
11) versus 9% (6/69), respectively ( ). The oddsPp .01
ratio for cancer in children with altered H19
methylation—6.0 (95%CI 1.3–26.5)—also did not
change significantly when these 12 patients were ex-
cluded, providing strong evidence that the risk of cancer
was specific for abnormalH19 methylation and was not
simply due to UPD. Therefore, abnormal H19 methyl-
ation appears to be specifically associated with increased
cancer risk in BWS.
Association of Macrosomia and Midline Abdominal-Wall
Defects with Altered Methylation of LIT1
We examined the association between molecular ab-
normalities in BWS and macrosomia, hypoglycemia,
macroglossia, ear pits or ear creases, hemihypertrophy,
and midline abdominal-wall defects. The frequency of
altered LIT1 methylation in patients with macrosomia
was significantly higher than that in patients without
macrosomia—60% (46/77) versus 18% (2/11), respec-
tively ( ; table 2). Similarly, the frequency of al-Pp .02
tered LIT1methylation in patients with midline abdom-
inal-wall defects was significantly higher than that in
patients without such defects—65% (41/63) versus 34%
(10/29), respectively ( ; table 2). For both mac-Pp .012
rosomia and midline abdominal-wall defects, we also
determined whether the increased frequency of altered
LIT1 methylation was simply due to UPD or an im-
printing disturbance extending throughout the 11p15
imprinted-gene domain. To address this possibility, we
excluded patients with either UPD or aberrant methyl-
ation of bothH19 and LIT1 from the analysis of macro-
somia ( ) and midline abdominal-wall defectsnp 11
( ). Excluding these patients, the frequency of al-np 12
tered LIT1 methylation among patients with macroso-
mia was still significantly higher than that in patients
without macrosomia—53% (35/66) versus 18% (2/11),
respectively ( ). Similarly, the frequency of alteredPp .03
LIT1 methylation among patients with midline abdom-
inal-wall defects remained significantly higher than that
in patients without such defects—60% (33/55) versus
24% (6/25), respectively ( ). Thus, the associ-Pp .003
ation between macrosomia and midline abdominal-wall
defects was specific for abnormal LIT1 methylation and
was not simply due to UPD. Therefore, abnormal LIT1
methylation appears to be specifically associated with
macrosomia and midline abdominal-wall defects in
BWS.
Association of Hemihypertrophy and Hypoglycemia
with Altered Methylation of Both LIT1 and H19
We determined whether the 12 patients with aberrant
methylation of both H19 and LIT1 (including the 9
patients with UPD) uniquely differed in phenotype in
some way—that is, we determined whether there were
any features specifically associated with such a domain-
wide alteration that were not found in association with
H19 or LIT1 alone. We found that hemihypertrophy
and hypoglycemia occurred significantly more fre-
quently in these patients. The frequency of hemihyper-
trophy among patients with UPD or aberrant methyla-
tion of bothH19 and LIT1was significantly higher than
that in patients without such defects—30% (10/33) ver-
sus 4% (2/49), respectively (P p .003). Similarly, the
frequency of hypoglycemia was 20% (10/49) and 5%
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Table 2
Significant Relationships between Phenotype and Molecular Abnormalities in BWS
PHENOTYPE
ABNORMAL H19 ABNORMAL LIT1 UPDa
Frequency P Frequency P Frequency P
Cancer:
Present 9/16 (56%)
.002b
6/16 (38%)
.19
5/16 (31%)
.03b
Absent 13/76 (17%) 45/76 (59%) 7/76 (9%)
Macrosomia:
Present 18/77 (23%)
1.0b
46/77 (60%)
.02
11/77 (14%)
.3b
Absent 2/11 (18%) 2/11 (18%) 0/11 (0%)
Hypoglycemia:
Present 14/49 (29%)
.4
28/49 (57%)
.9
10/49 (20%)
.05b
Absent 8/43 (19%) 23/43 (53%) 2/43 (5%)
Hemihypertrophy:
Present 12/33 (36%)
.07c
19/33 (58%)
.9
10/33 (30%)
.003b
Absent 10/59 (17%) 32/59 (54%) 2/49 (4%)
Midline defects:
Present 14/63 (22%)
.76
41/63 (65%)
.012
8/63 (13%)
1.0b
Absent 8/29 (28%) 10/29 (34%) 4/29 (14%)
a Plus cases of abnormal methylation of both H19 and LIT1.
b Determined by Fisher’s exact test.
c if patients with UPD are excluded; thus, there is no independent association withH19Pp .5
methylation.
(2/43), respectively (P p .05). Thus, in BWS, abnormal
methylation of both H19 and LIT1 appears to be spe-
cifically associated with hemihypertrophy and hypogly-
cemia. As expected, in these 12 patients, there was also
a significantly increased frequency of cancer (table 2),
since cancer is associated with abnormal methylation of
only H19 (table 2). Somewhat surprisingly, that was not
the case for macrosomia or midline abdominal-wall de-
fects, which showed no significant increase in frequency
in these 12 patients, even though these abnormalities are
associated with abnormal methylation of only LIT1 (ta-
ble 2).
Discussion
BWS is a model for the study of epigenetics in human
disease, since it involves multiple imprinted genes, as
well as both increased risk of cancer and a wide variety
of birth defects. BWS offers a unique opportunity to
understand the relationship between epigenotype and
phenotype, because of its genetic heterogeneity and sub-
stantial variability in expressivity of the phenotype. The
large number of patients in this study and their complete
phenotypic assessment allowed for subgroup analysis to
assess specific epigenotype-phenotype relationships. We
focused this investigation on epigenetic changes in this
disorder—specifically, altered methylations of H19 and
LIT1, which account for most of the known alterations
in these patients. There were three significant epigeno-
type-phenotype associations revealed by this analysis: (1)
cancer is significantly associated with altered methyla-
tion of H19; (2) macrosomia and midline abdominal-
wall defects are significantly associated with altered
LIT1 methylation; and (3) hypoglycemia and hemihy-
pertrophy are significantly associated with UPD or al-
tered methylation of both LIT1 and H19.
The association, in BWS, between paternal UPD of
11p15 and cancer was initially suggested by Henry et al.
(1993), in a small case series in which three of six patients
with UPD had cancer. Similarly, because of the small
number of patients with cancer ( ), Bliek et al.np 7
(2001) could not perform a statistical analysis distin-
guishing the risk of cancer with UPD from the risk of
cancer with abnormal H19 methylation. Here, we show
that this risk is specific for abnormal H19 methylation.
Given that the epigenetic alteration associated with
cancer risk in BWS is altered methylation of the H19
DMR, what might be the mechanism for cancer in these
patients? The only known function of H19 is the reg-
ulation of IGF2 expression by the H19 DMR, since
knockout of the H19 RNA itself has no effect in mice
(Schmidt et al. 1999). We and others previously showed
that sporadically occurring embryonal tumors (i.e.,
those not occurring in the context of BWS) undergo
LOI of IGF2 (Ogawa et al. 1993; Rainier et al. 1993).
We found that LOI of IGF2, which involves activation
of the normally silent maternal allele, is often coupled,
in these tumors, to abnormal methylation of the ma-
ternal allele of the H19 DMR (Moulton et al. 1994;
Steenman et al. 1994). This methylation appears to in-
hibit binding of CTCF or of other insulator proteins to
the normally unmethylated maternal H19 DMR, thus
allowing access by a shared enhancer to the IGF2 pro-
moter and thereby causing biallelic expression of IGF2
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Figure 1 One-megabase region of chromosome 11p15.5 con-
taining two imprinted-gene subdomains. The more centromeric sub-
domain includes p57KIP2, LIT1, and KvLQT1, and the more telomeric
subdomain includes IGF2 and H19. Unblackened boxes represent
transcriptionally active genes, and arrows indicate the transcriptional
orientation; octagons represent the DMRs analyzed here, and black-
ened octagons indicate methylation. Paternal chromosome is desig-
nated by “pat”; maternal chromosome is designated by “mat.” (Not
all genes are listed.)
(reviewed by Feinberg [2001]). We hypothesized that a
similar mechanism may be at work in patients with
constitutional epigenetic alterations (i.e., in patients
with BWS). Our study supports a role for theH19DMR
in the pathogenesis of human cancer. The human H19
DMR extends from the promoter to 6 kb upstream from
H19, and the region examined here is the same (pro-
moter region) as that identified earlier by us and others
as showing abnormal methylation in Wilms tumor
(Moulton et al. 1994; Steenman et al. 1994). We have
found that altered methylation in Wilms tumor also
includes CTCF-binding sites 5 kb upstream and within
the DMR (Cui et al. 2001), and it will be of interest in
further studies to map these sites precisely in BWS.
IGF2 imprinting could not be directly analyzed in
most patients, since it would require examination of
expressing tissues as well as informativeness for the req-
uisite polymorphic markers to distinguish individual al-
leles. One problem with examining IGF2 in cultured
fibroblasts is that we have found IGF2 to undergo loss
of imprinting in cultured normal fibroblasts (E. L.
Niemitz and A. P. Feinberg, unpublished data), which
may explain the apparent discordance of IGF2 imprint-
ing and H19 methylation reported by Joyce et al.
(1997). In the study by Bliek et al. (2001), the source
of DNA was not given. We also found that H19 meth-
ylation, but not LIT1 methylation, is reduced in cul-
tured skin fibroblasts; however, in the present study,
there was no difference in the frequency of increased
H19 methylation among samples from patients with
BWS derived from blood or from cultured skin fibro-
blasts, and thus altered imprinting of IGF2 may be
methylation independent—at least at the H19 DMR.
Note that the source of DNA did not affect the results,
since the association between increased H19 methyla-
tion and cancer was seen even if the patients with fi-
broblast samples were excluded.
Given that, in BWS, the epigenetic alteration asso-
ciated with midline abdominal-wall defects and macro-
somia is altered LIT1 methylation, what is the mech-
anism for such congenital malformations in these
patients? The function of LIT1 is unknown, although
we have previously hypothesized that abnormal hypo-
methylation of LIT1 might cause the silencing of the
nearby p57KIP2 gene, by a mechanism similar to the si-
lencing of IGF2 by the H19 DMR (Lee et al. 1999). In
support of this hypothesis, p57KIP2 is mutated in a small
fraction of patients with BWS (Lee et al. 1997a;O’Keefe
et al. 1997). Furthermore, knockout mice lacking a
functional p57KIP2 gene show similar midline abdomi-
nal-wall defects (Zhang et al. 1997). As with IGF2,
direct examination of p57KIP2 imprinting would require
analysis of expressing tissues, such as kidney and
tongue, which are not readily available in a large cohort
of patients.
These observations fit very well a two-domain hy-
pothesis for BWS we have proposed elsewhere (Lee et
al. 1999). By this model, 11p15 contains two separate
imprinted subdomains (fig. 1). The more telomeric sub-
domain includes IGF2 and H19, and the more cen-
tromeric subdomain includes p57KIP2, LIT1, and
KvLQT1. BWS arises by the disrupted imprinting of
either subdomain. The likely target gene for BWS is
IGF2 in the more telomeric subdomain and p57KIP2 in
the more centromeric subdomain. By this model, a
DMR lies between a given BWS target gene and its
enhancer, and abnormal hypermethylation permits ac-
cess of this enhancer to the maternal allele of IGF2 on
the maternal allele, while abnormal hypomethylation
inhibits access of this enhancer to the maternal allele of
p57KIP2. The chromosomal rearrangements in KvLQT1
would have the same effect (Lee et al. 1997b). Support
for our model comes from a comparative genomic anal-
ysis showing a similar organization in the mouse (On-
yango et al. 2001) and from a study indicating that the
p57KIP2 enhancer is in the location our model predicts,
although the enhancer itself was not identified in that
study (Cleary et al. 2001). The data in the current study
would suggest that the more centromeric subdomain is
involved primarily in growth regulation and that the
more telomeric subdomain is involved primarily in tu-
mor suppression.
An additional conclusion of this study is that hypo-
glycemia and hemihypertrophy are associated specifi-
cally with UPD or with methylation abnormalities af-
fecting both H19 and LIT1. We address each of these
separately:
1. Hemihypertrophy. This is an asymmetric enlarge-
ment of one half of the body or a portion thereof. We
suggest that hemihypertrophy in BWS is simply the mo-
saic form of macrosomia, which was associated with
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altered methylation of LIT1. To date, all of the patients
with UPD reported—including those studied here—are
mosaic. We predict that there is an asymmetric spatial
distribution of UPD on the two sides of the body in these
patients.
2. Hypoglycemia. The association between hypogly-
cemia and UPD (or abnormal methylation of both genes)
and the lack of association between hypoglycemia and
either methylation of only H19 or only LIT1 suggest
that another gene on 11p15 may contribute to this phe-
notype. Such a gene would also undergo paternal du-
plication in patients with UPD. What gene could this
be? There are several additional imprinted genes on
11p15 (reviewed by Feinberg [1999]). One intriguing
possibility is that the insulin gene (INS [MIM 176730]),
although not generally thought to be imprinted, may
show imprinting in the yolk sac (Moore et al. 2001). It
will be of interest to examine the imprinting of the in-
sulin gene in the developing pancreas.
As with any case-cohort study, our analysis is asso-
ciated with several limitations. We did not obtain bio-
logical samples from all patients in the BWS Registry;
however, the frequency of cancer and other phenotypic
features did not differ significantly between those with
and without molecular analysis. Another limitation is
that we were not able to assess the relationship between
phenotype and p57KIP2 mutations or KvLQT1 rear-
rangements, because of the low frequency of these al-
terations; in our previous work and work by others, the
frequency of p57KIP2 mutations is 5% (Lee et al. 1997a;
O’Keefe et al. 1997), and the frequency of KvLQT1
rearrangements is !1% (reviewed by Elias et al. [1998]).
The focus of the present study has been epigenetic al-
terations, rather than mutations.
Finally, we have here reported the first examples of
abnormal methylation that affects both LIT1 andH19,
in the absence of UPD. These results suggest that these
three patients exhibit disrupted methylation throughout
the 11p15 imprinted-gene domain. We postulate that
there is a hierarchical epigenetic organization of this
domain, with some patients showing epigenetic disrup-
tion including that of LIT1, with others showing epi-
genetic disruption including that of H19, and with a
final group showing epigenetic disruption affecting the
domain as a whole. Such patients may have “imprinting
center” mutations analogous to those seen in some pa-
tients with Prader-Willi syndrome (MIM 176270) or
Angelman syndrome (MIM 105830) with microdele-
tions (Buiting et al. 2000).
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